Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Livingston, New Jersey • Portland, Oregon • Richland, Washington + 2 more

Conditions: Acute Myeloid Leukemia
Interventions: BL-8040, Atezolizumab; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 60 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Houston, Texas • Milwaukee, Wisconsin

Conditions: Chronic Rhinosinusitis With Nasal Polyps, Nasal Polyps
Interventions: Omalizumab; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: DHES0815A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more

Conditions: Solid Cancers, Non-Hodgkin's Lymphoma
Interventions: Fulvestrant, GDC-0032, Letrozole, Midazolam; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more

Conditions: Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
Interventions: Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Cobimetinib, Vismodegib, Alectinib, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 60
States / cities: Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more

Conditions: Coal Workers' Pneumoconiosis (Complicated)
Interventions: Pirfenidone; Drug
Lead sponsor: Pulmonary Research of Abingdon, LLC; Other
Eligibility: 40 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Abingdon, Virginia

Conditions: Breast Cancer, Carcinoma of the Breast
Interventions: Paclitaxel, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 20
States / cities: San Francisco, California • Maywood, Illinois • Indianapolis, Indiana + 13 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Interventions: Carboplatin, Atezolizumab, Etoposide, Total Body Irradiation, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging; Drug · Biological · Radiation + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hepatocellular Carcinoma
Interventions: Y-90 TARE, Atezolizumab, Bevacizumab; Other · Drug
Lead sponsor: Aiwu Ruth He, MD; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Carcinoma, Transitional Cell
Interventions: Atezolizumab; Drug
Lead sponsor: Lawrence Fong; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: San Francisco, California

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Neoadjuvant Atezolizumab in Localized Bladder Cancer

About this Genentech, Inc. sponsor directory page